Xencor (XNCR) Competitors $16.35 +0.13 (+0.80%) As of 12:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends XNCR vs. VRNA, KRYS, RARE, RNA, SWTX, ADMA, OGN, BHVN, ALVO, and PTCTShould you be buying Xencor stock or one of its competitors? The main competitors of Xencor include Verona Pharma (VRNA), Krystal Biotech (KRYS), Ultragenyx Pharmaceutical (RARE), Avidity Biosciences (RNA), SpringWorks Therapeutics (SWTX), ADMA Biologics (ADMA), Organon & Co. (OGN), Biohaven (BHVN), Alvotech (ALVO), and PTC Therapeutics (PTCT). These companies are all part of the "pharmaceutical products" industry. Xencor vs. Verona Pharma Krystal Biotech Ultragenyx Pharmaceutical Avidity Biosciences SpringWorks Therapeutics ADMA Biologics Organon & Co. Biohaven Alvotech PTC Therapeutics Xencor (NASDAQ:XNCR) and Verona Pharma (NASDAQ:VRNA) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends, profitability and community ranking. Do institutionals & insiders hold more shares of XNCR or VRNA? 85.9% of Verona Pharma shares are owned by institutional investors. 5.2% of Xencor shares are owned by company insiders. Comparatively, 4.8% of Verona Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community favor XNCR or VRNA? Xencor received 177 more outperform votes than Verona Pharma when rated by MarketBeat users. However, 80.84% of users gave Verona Pharma an outperform vote while only 73.44% of users gave Xencor an outperform vote. CompanyUnderperformOutperformXencorOutperform Votes50673.44% Underperform Votes18326.56% Verona PharmaOutperform Votes32980.84% Underperform Votes7819.16% Which has higher valuation & earnings, XNCR or VRNA? Verona Pharma has lower revenue, but higher earnings than Xencor. Verona Pharma is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXencor$168.34M6.86-$126.09M-$3.20-5.16Verona Pharma$460K11,190.04-$54.37M-$1.92-33.54 Which has more volatility & risk, XNCR or VRNA? Xencor has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Comparatively, Verona Pharma has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Is XNCR or VRNA more profitable? Verona Pharma has a net margin of 0.00% compared to Xencor's net margin of -232.77%. Xencor's return on equity of -30.92% beat Verona Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Xencor-232.77% -30.92% -21.74% Verona Pharma N/A -79.54%-43.49% Does the media prefer XNCR or VRNA? In the previous week, Verona Pharma had 6 more articles in the media than Xencor. MarketBeat recorded 8 mentions for Verona Pharma and 2 mentions for Xencor. Verona Pharma's average media sentiment score of 0.84 beat Xencor's score of 0.00 indicating that Verona Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xencor 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Verona Pharma 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer XNCR or VRNA? Xencor currently has a consensus target price of $34.88, indicating a potential upside of 111.36%. Verona Pharma has a consensus target price of $57.14, indicating a potential downside of 11.26%. Given Xencor's higher probable upside, equities analysts clearly believe Xencor is more favorable than Verona Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xencor 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Verona Pharma 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 SummaryXencor and Verona Pharma tied by winning 8 of the 16 factors compared between the two stocks. Get Xencor News Delivered to You Automatically Sign up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XNCR vs. The Competition Export to ExcelMetricXencorPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.15B$6.98B$5.82B$9.18BDividend YieldN/A2.90%5.25%3.99%P/E Ratio-5.156.0024.8119.27Price / Sales6.86320.79465.4979.23Price / CashN/A72.6944.6537.93Price / Book1.506.457.635.18Net Income-$126.09M$138.54M$3.19B$245.95M7 Day Performance1.73%1.38%1.18%1.70%1 Month Performance-14.24%1.10%3.21%1.19%1 Year Performance-31.68%-0.32%20.06%15.79% Xencor Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XNCRXencor3.5946 of 5 stars$16.35+0.8%$34.88+113.3%-32.8%$1.15B$168.34M-5.12280Upcoming EarningsVRNAVerona Pharma2.0745 of 5 stars$58.75-2.5%$53.14-9.5%+273.5%$4.70B$460,000.00-30.6030KRYSKrystal Biotech4.4851 of 5 stars$154.53-0.2%$206.67+33.7%+38.0%$4.44B$241.52M87.31210Earnings ReportAnalyst ForecastShort Interest ↓News CoverageGap DownRAREUltragenyx Pharmaceutical4.7086 of 5 stars$44.78-1.3%$92.43+106.4%-10.8%$4.14B$522.75M-6.921,276Earnings ReportAnalyst ForecastRNAAvidity Biosciences1.7525 of 5 stars$34.31-1.7%$65.80+91.8%+125.7%$4.09B$9.56M-11.91190SWTXSpringWorks Therapeutics2.1439 of 5 stars$54.00+34.1%$70.00+29.6%+7.5%$4.02B$5.45M-13.92230Analyst RevisionHigh Trading VolumeADMAADMA Biologics3.5491 of 5 stars$16.66-0.3%$21.25+27.6%+206.3%$3.94B$258.21M59.50530Positive NewsOGNOrganon & Co.4.8763 of 5 stars$15.04+2.8%$21.33+41.9%-17.4%$3.87B$6.26B2.9810,000Earnings ReportDividend AnnouncementBHVNBiohaven3.4006 of 5 stars$38.25-0.5%$63.00+64.7%-20.5%$3.87BN/A-4.09239Short Interest ↓Gap DownALVOAlvotech3.0997 of 5 stars$12.75-1.2%$18.00+41.2%-20.5%$3.84B$93.38M-6.891,026News CoveragePositive NewsPTCTPTC Therapeutics3.8048 of 5 stars$49.82+0.7%$57.85+16.1%+90.8%$3.84B$900.66M-8.391,410Analyst DowngradeNews Coverage Related Companies and Tools Related Companies Verona Pharma Alternatives Krystal Biotech Alternatives Ultragenyx Pharmaceutical Alternatives Avidity Biosciences Alternatives SpringWorks Therapeutics Alternatives ADMA Biologics Alternatives Organon & Co. Alternatives Biohaven Alternatives Alvotech Alternatives PTC Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:XNCR) was last updated on 2/19/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xencor, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xencor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
